Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease

Kraft, Andrea; Weindel, Karin; Ochs, Andreas; Marth, Christian; Zmija, B S Jörg; Schumacher, B S Petra; Unger, Clemens; Marmé, Dieter; Gastl, Günther

doi:10.1002/(sici)1097-0142(19990101)85:1<178::aid-cncr25>3.0.co;2-7

Cited by 335 publications

(205 citation statements)

References 19 publications

Supporting

Mentioning

180

Contrasting

Unclassified

Order By: Relevance

“…N.S, not significant production of ascites and carcinomatosis [17,18]. Indeed, Kraft et al [19] reported that VEGF may play an important role in tumor progression and the formation of malignant effusions. Mesiano et al [20] demonstrated that the neutralization of VEGF activity may have clinical applications in inhibiting malignant ascites formation in ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

VEGF significance in peritoneal recurrence from gastric cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

VEGF significance in peritoneal recurrence from gastric cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Three of those studies, performed with the same immunoassay as the one we used, reported median serum VEGF levels ranging from 186 to 368 pg ml À1 , with a considerable range between minimum and maximum levels (10 to 2426 pg ml À1 in the series of Kraft et al, 1999) (Salven et al, 1999b;Adams et al, 2000). These results are consistent with our findings (median: 302 pg ml À1 ; range 31 -3183) confirming the strong correlation between serum VEGF and platelet count (Salgado et al, 1999).…”

Section: Prognostic Value Of Angiogenic Factors In Breast Cancer T Bamentioning

confidence: 92%

Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients

et al. 2003

View full text Add to dashboard Cite

Prediction of survival for patients with metastatic breast cancer is often inaccurate and may be helped by new biological parameters. Tumour growth being angiogenesis-dependent, it has been hypothesised that the assessment of angiogenic factor production might reflect the clinical behaviour of cancer progression. This study was designed to investigate the clinical significance of vascular endothelial growth factor (VEGF) and interleukin 6 (IL-6) in hormone-refractory metastatic breast cancer. Serum and plasma concentrations of VEGF and serum concentration of IL-6 were measured in 87 patients with a fully documented history of metastatic breast cancer using an enzyme-linked immunoassay. All patients had detectable levels of VEGF, whereas 39% patients had detectable serum levels of IL-6. There was a positive correlation between IL-6 levels and the theoretical VEGF load of platelets (Po0.001). The presence of high levels of serum IL-6, but not VEGF, was significantly correlated to a shorter survival. In a multivariate analysis along with clinical prognostic parameters, serum IL-6 was identified as an independent adverse prognostic variable for overall survival (Po0.001). These results indicate that serum IL-6 levels correlate to poor survival in patients with hormone-refractory metastatic breast cancer. Vascular endothelial growth factor serum and plasma levels are not useful indicators of prognosis for these patients.

show abstract

“…Tumour cells and/or blood platelets may be the major sources of VEGF in cancer patients, particularly in metastatic disease. In fact, the majority of cancer patients with metastatic disease show elevated VEGF levels in serum (Kraft et al, 1999). Moreover, increasing VEGF serum levels may herald tumour relapse or progression.…”

Section: Sirmentioning

confidence: 99%